- Home
- TTNP vs CDT Comparison
TTNP vs CDT Comparison
Compare TTNP & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTNP
- CDT
- Stock Information
- Founded
- TTNP 1991
- CDT 2019
- Country
- TTNP United States
- CDT United States
- Employees
- TTNP N/A
- CDT N/A
- Industry
- TTNP Biotechnology: Biological Products (No Diagnostic Substances)
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- TTNP Health Care
- CDT Health Care
- Exchange
- TTNP Nasdaq
- CDT Nasdaq
- Market Cap
- TTNP 5.4M
- CDT 4.6M
- IPO Year
- TTNP 1996
- CDT N/A
- Fundamental
- Price
- TTNP $4.23
- CDT $1.18
- Analyst Decision
- TTNP
- CDT
- Analyst Count
- TTNP 0
- CDT 0
- Target Price
- TTNP N/A
- CDT N/A
- AVG Volume (30 Days)
- TTNP 92.5K
- CDT 160.1K
- Earning Date
- TTNP 08-14-2025
- CDT 08-14-2025
- Dividend Yield
- TTNP N/A
- CDT N/A
- EPS Growth
- TTNP N/A
- CDT N/A
- EPS
- TTNP N/A
- CDT N/A
- Revenue
- TTNP N/A
- CDT N/A
- Revenue This Year
- TTNP N/A
- CDT N/A
- Revenue Next Year
- TTNP N/A
- CDT N/A
- P/E Ratio
- TTNP N/A
- CDT N/A
- Revenue Growth
- TTNP N/A
- CDT N/A
- 52 Week Low
- TTNP $3.03
- CDT $1.16
- 52 Week High
- TTNP $6.43
- CDT $274.80
- Technical
- Relative Strength Index (RSI)
- TTNP 45.73
- CDT 24.09
- Support Level
- TTNP $3.58
- CDT $1.47
- Resistance Level
- TTNP $4.45
- CDT $1.36
- Average True Range (ATR)
- TTNP 0.37
- CDT 0.11
- MACD
- TTNP -0.08
- CDT -0.01
- Stochastic Oscillator
- TTNP 36.93
- CDT 3.51
About TTNP Titan Pharmaceuticals Inc.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
About CDT Conduit Pharmaceuticals Inc.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.